James N. Topper

CIK: 0001341382

Transaction Breakdown

Open Market Buys (P)14 (87.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (12.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

ATTO

Attovia Therapeutics, Inc.

Director

PHAT

Phathom Pharmaceuticals, Inc.

Director10% Owner

NAMS

NewAmsterdam Pharma Co N.V.

Director

Discretionary Trading P&L

Holdings

Transaction History (16 total)

PHAT
Phathom Pharmaceuticals, Inc.
May 19, 2026
Award(A)
Direct
24.1K shares-
NAMS
NewAmsterdam Pharma Co N.V.
Sep 15, 2025
Purchase(P)
Indirect
660 shares at avg. $23.70$16K
NAMS
NewAmsterdam Pharma Co N.V.
Sep 8, 2025
Purchase(P)
Indirect
1.3K shares at avg. $24.99$31K
NAMS
NewAmsterdam Pharma Co N.V.
Aug 11, 2025
Purchase(P)
Indirect
471 shares at avg. $23.98$11K
NAMS
NewAmsterdam Pharma Co N.V.
Jun 25, 2025
Purchase(P)
Indirect
1.3K shares at avg. $18.26$23K
NAMS
NewAmsterdam Pharma Co N.V.
Jun 24, 2025
Purchase(P)
Indirect
2.5K shares at avg. $18.43$46K
NAMS
NewAmsterdam Pharma Co N.V.
Jun 16, 2025
Purchase(P)
Indirect
8.6K shares at avg. $19.50$167K
PHAT
Phathom Pharmaceuticals, Inc.
Jun 3, 2025
Award(A)
Direct
10.5K shares-
PHAT
Phathom Pharmaceuticals, Inc.
May 21, 2025
Purchase(P)
Indirect
3.8K shares at avg. $3.86$15K
PHAT
Phathom Pharmaceuticals, Inc.
May 14, 2025
Purchase(P)
Indirect
6.3K shares at avg. $3.32$21K
PHAT
Phathom Pharmaceuticals, Inc.
May 13, 2025
Purchase(P)
Indirect
1.1K shares at avg. $3.16$4K
PHAT
Phathom Pharmaceuticals, Inc.
May 12, 2025
Purchase(P)
Indirect
12.6K shares at avg. $3.04$38K
PHAT
Phathom Pharmaceuticals, Inc.
May 9, 2025
Purchase(P)
Indirect
33.4K shares at avg. $3.19$107K
PHAT
Phathom Pharmaceuticals, Inc.
May 9, 2025
Purchase(P)
Indirect
2.2K shares at avg. $3.62$8K
NAMS
NewAmsterdam Pharma Co N.V.
Mar 26, 2025
Purchase(P)
Indirect
1.1K shares at avg. $22.49$26K
NAMS
NewAmsterdam Pharma Co N.V.
Mar 4, 2025
Purchase(P)
Indirect
4K shares at avg. $21.02$84K

		Type	Shares	Price		Ownership
May 19, 2026	PHAT Phathom Pharmaceuticals, Inc.	Award(A)	24,122	-	$0	Direct
Sep 15, 2025	NAMS NewAmsterdam Pharma Co N.V.	Purchase(P)	660	$23.70	$15,639	Indirect
Sep 8, 2025	NAMS NewAmsterdam Pharma Co N.V.	Purchase(P)	1,260	$24.99	$31,487	Indirect
Aug 11, 2025	NAMS NewAmsterdam Pharma Co N.V.	Purchase(P)	471	$23.98	$11,294	Indirect
Jun 25, 2025	NAMS NewAmsterdam Pharma Co N.V.	Purchase(P)	1,260	$18.26	$23,012	Indirect
Jun 24, 2025	NAMS NewAmsterdam Pharma Co N.V.	Purchase(P)	2,520	$18.43	$46,454	Indirect
Jun 16, 2025	NAMS NewAmsterdam Pharma Co N.V.	Purchase(P)	8,584	$19.50	$167,381	Indirect
Jun 3, 2025	PHAT Phathom Pharmaceuticals, Inc.	Award(A)	10,500	-	-	Direct
May 21, 2025	PHAT Phathom Pharmaceuticals, Inc.	Purchase(P)	3,780	$3.86	$14,609	Indirect
May 14, 2025	PHAT Phathom Pharmaceuticals, Inc.	Purchase(P)	6,300	$3.32	$20,919	Indirect
May 13, 2025	PHAT Phathom Pharmaceuticals, Inc.	Purchase(P)	1,120	$3.16	$3,543	Indirect
May 12, 2025	PHAT Phathom Pharmaceuticals, Inc.	Purchase(P)	12,601	$3.04	$38,301	Indirect
May 9, 2025	PHAT Phathom Pharmaceuticals, Inc.	Purchase(P)	33,376	$3.19	$106,563	Indirect
May 9, 2025	PHAT Phathom Pharmaceuticals, Inc.	Purchase(P)	2,226	$3.62	$8,053	Indirect
Mar 26, 2025	NAMS NewAmsterdam Pharma Co N.V.	Purchase(P)	1,135	$22.49	$25,521	Indirect
Mar 4, 2025	NAMS NewAmsterdam Pharma Co N.V.	Purchase(P)	4,005	$21.02	$84,203	Indirect

1-16 of 16 transactions

About Topper James N

Topper James N (SEC CIK 0001341382) files insider reports with the SEC as Director of Attovia Therapeutics, Inc. (ATTO), Director of Phathom Pharmaceuticals, Inc. (PHAT) and Director of NewAmsterdam Pharma Co N.V. (NAMS).

Signal8 holds 13 ownership filings by Topper James N (1 Form 3, 12 Form 4), filed between Mar 6, 2025 and Aug 4, 2026. Those filings report 16 transactions, from Mar 4, 2025 to May 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Topper James N's filings is in SAN CARLOS, CA.

Recent filings by Topper James N

May 19, 2026: Grant or award of PHAT shares (Form 4, code A).
Sep 15, 2025: Open-market purchase of NAMS shares (Form 4, code P).
Sep 8, 2025: Open-market purchase of NAMS shares (Form 4, code P).
Aug 11, 2025: Open-market purchase of NAMS shares (Form 4, code P).
Jun 25, 2025: Open-market purchase of NAMS shares (Form 4, code P).

Other insiders filing for Attovia Therapeutics, Inc. (ATTO)

Fu Tao, President and CEO
Chan Steven, Chief Financial Officer
WALSH COLIN, Director
GOLDMAN SACHS GROUP INC, Officer
Deep Track Biotechnology Master Fund, Ltd., 10% Owner
venBio Global Strategic Fund IV, L.P., 10% Owner

How to read Form 4 transaction codes